The BARI 2D Randomized Trial of Different Treatment Strategies in Type 2 Diabetes Mellitus with Stable Ischemic Heart Disease. Impact of Treatment Strategy on Cardiac Mortality and Myocardial Infarction

Background The Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial (BARI 2D) in 2,368 patients with stable ischemic heart disease assigned pre-randomization to percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) strata reported similar 5-year all cause mortality rates with insulin sensitization (IS) vs. insulin provision (IP) therapy and with a strategy of prompt initial coronary revascularization and intensive medical therapy (REV) or intensive medical therapy alone with REV reserved for clinical indication(s) (IMT). In this report, we examine the predefined secondary endpoints of cardiac death and myocardial infarction (MI).